Special Interest Guidances/Information |
Date Posted |
Consideration of Uncertainty in Making Benefit-Risk Determinations in Medical Device Premarket Approvals, De Novo Classifications, and Humanitarian Device Exemptions: Guidance for Industry and Food and Drug Administration Staff – Final |
30 August 2019 |
Factors to Consider When Making Benefit-Risk Determinations in Medical Device Premarket Approval and De Novo Classifications: Guidance for Industry and Food and Drug Administration Staff – Final |
30 August 2019 |
Guidance for Industry: Policy Related to Cranberry Products with Added Flavorings – Final |
30 August 2019 |
Placebos and Blinding in Randomized Controlled Cancer Clinical Trials for Drug and Biological Products Guidance for Industry – Final |
28 August 2019 |
Male Breast Cancer: Developing Drugs for Treatment: Draft Guidance for Industry – Draft |
27 August 2019 |
CVM GFI #257 (VICH GL57) Studies to Evaluate the Metabolism and Residue Kinetics of Veterinary Drugs in Food-Producing Species: Marker Residue Depletion Studies to Establish Product Withdrawal Periods in Aquatic Species – Final |
19 August 2019 |
Guidance for Industry: Converting Units of Measure for Folate, Niacin, and Vitamins A, D, and E on the Nutrition and Supplement Facts Labels – Final |
15 August 2019 |
Osteoporosis: Nonclinical Evaluation of Drugs Intended for Treatment Guidance for Industry: Guidance for Industry – Final |
14 August 2019 |
Child-Resistant Packaging Statements in Drug Product Labeling Guidance for Industry – Final |
13 August 2019 |
Gastroparesis: Clinical Evaluation of Drugs for Treatment Guidance for Industry – Draft |
13 August 2019 |
Fabry Disease: Developing Drugs for Treatment Guidance for Industry – Draft |
07 August 2019 |
FDA Deems Certain Tobacco Products Subject to FDA Authority, Sales and Distribution Restrictions, and Health Warning Requirements for Packages and Advertisements: Guidance for Industry – Final |
02 August 2019 |
Testing and Labeling Medical Devices for Safety in the Magnetic Resonance (MR) Environment: Draft Guidance for Industry and Food and Drug Administration Staff – Draft |
02 August 2019 |
“Harmful and Potentially Harmful Constituents” in Tobacco Products as Used in Section 904(e) of the Federal Food, Drug, and Cosmetic Act: Guidance for Industry and FDA Staff – Final |
02 August 2019 |
Oncology Therapeutic Radiopharmaceuticals: Nonclinical Studies and Labeling Recommendations Guidance for Industry – Final |
01 August 2019 |
Bacterial Vaginosis: Developing Drugs for Treatment Guidance for Industry – Final |
31 July 2019 |
E8(R1) GENERAL CONSIDERATIONS FOR CLINICAL STUDIES – Draft |
31 July 2019 |
General Clinical Pharmacology Considerations for Neonatal Studies for Drugs and Biological Products Guidance for Industry – Draft |
31 July 2019 |
Pathology Peer Review in Nonclinical Toxicology Studies: Questions and Answers – Draft |
31 July 2019 |
Uncomplicated Urinary Tract Infections: Developing Drugs for Treatment Guidance for Industry – Final |
31 July 2019 |
Vulvovaginal Candidiasis: Developing Drugs for Treatment – Final |
31 July 2019 |
Rare Pediatric Disease Priority Review Vouchers: Draft Guidance for Industry – Draft |
30 July 2019 |
Delayed Graft Function in Kidney Transplantation: Developing Drugs for Prevention Guidance for Industry – Final |
26 July 2019 |
Metal Expandable Biliary Stents – Premarket Notification (510(k)) Submissions: Guidance for Industry and Food and Drug Administration Staff – Final |
26 July 2019 |
CVM GFI #181 Blue Bird Medicated Feed Labels – Final |
23 July 2019 |
Providing Regulatory Submissions in Electronic Format–Submission of Manufacturing Establishment Information Guidance for Industry – Draft |
23 July 2019 |
Postmarketing Safety Reporting for Combination Products: Guidance for Industry and FDA Staff – Final |
22 July 2019 |
Submitting Next Generation Sequencing Data to the Division of Antiviral Products Guidance for Industry Technical Specifications Document – Final |
18 July 2019 |
Advanced Prostate Cancer: Developing Gonadotropin-Releasing Hormone Analogues Guidance for Industry: Draft Clinical/Medical – Draft |
17 July 2019 |
Providing Regulatory Submissions in Electronic Format — Certain Human Pharmaceutical Product Applications and Related Submissions Using the eCTD Specifications Guidance for Industry – Draft |
16 July 2019 |
Establishing Effectiveness and Safety for Hormonal Drug Products Intended to Prevent Pregnancy Guidance for Industry – Draft |
11 July 2019 |
Live Case Presentations During Investigational Device Exemption (IDE) Clinical Trials: Guidance for Institutional Review Boards, Industry, Clinical Investigators, and Food and Drug Administration Staff – Final |
11 July 2019 |
Population Pharmacokinetics – Draft |
11 July 2019 |
Harmonizing Compendial Standards With Drug Application Approval Using the USP Pending Monograph Process Guidance for Industry – Draft |
10 July 2019 |
Using the Inactive Ingredient Database Guidance for Industry – Draft |
10 July 2019 |
Risk Evaluation and Mitigation Strategies: Modifications and Revisions Guidance for Industry – Final |
09 July 2019 |
Compliance Policy for Certain Compounding of Oral Oxitriptan (5-HTP) Drug Products for Patients With Tetrahydrobiopterin (BH4) Deficiency Immediately in Effect Guidance for Industry – Final |
05 July 2019 |
Center for Devices and Radiological Health (CDRH) Appeals Processes: Guidance for Industry and Food and Drug Administration Staff – Final |
02 July 2019 |
Center for Devices and Radiological Health (CDRH) Appeals Processes: Questions and Answers About 517A: Guidance for Industry and Food and Drug Administration Staff – Final |
02 July 2019 |
Drug Abuse and Dependence Section of Labeling for Human Prescription Drug and Biological Products — Content and Format Guidance for Industry – Draft |
01 July 2019 |
Instructions for Use — Patient Labeling for Human Prescription Drug and Biological Products and Drug-Device and Biologic-Device Combination Products — Content and Format Guidance for Industry – Draft |
01 July 2019 |
Epidermolysis Bullosa: Developing Drugs for Treatment of Cutaneous Manifestations; Guidance for Industry – Final |
28 June 2019 |
Marketing Clearance of Diagnostic Ultrasound Systems and Transducers : Guidance for Industry and Food and Drug Administration Staff – Final |
27 June 2019 |
Treatment for Heart Failure: Endpoints for Drug Development Guidance for Industry – Draft |
27 June 2019 |
Clinical Investigations for Prostate Tissue Ablation Devices: Draft Guidance for Industry and Food and Drug Administration Staff – Draft |
26 June 2019 |
E19 OPTIMISATION OF SAFETY DATA COLLECTION – Draft |
26 June 2019 |
M10 BIOANALYTICAL METHOD VALIDATION – Draft |
26 June 2019 |
Draft Guidance for Industry: Reducing Microbial Food Safety Hazards in the Production of Seed for Sprouting – Draft |
24 June 2019 |
Providing Regulatory Submissions in Electronic and Non-Electronic Format—Promotional Labeling and Advertising Materials for Human Prescription Drugs – Final |
21 June 2019 |
Opioid Analgesic Drugs: Considerations for Benefit-Risk Assessment Framework Guidance for Industry – Draft |
20 June 2019 |
Guidance for Industry: Determining the Number of Employees for Purposes of the “Small Business” Definition in Parts 117 and 507 – Final |
19 June 2019 |
Guidance for Industry: Declaration of Added Sugars on Honey, Maple Syrup, Other Single-Ingredient Sugars and Syrups, and Certain Cranberry Products – Final |
18 June 2019 |
Mouse Embryo Assay for Assisted Reproduction Technology Devices – Draft |
13 June 2019 |
Testing for Biotin Interference in In Vitro Diagnostic Devices: Draft Draft Guidance for Industry – Draft |
13 June 2019 |
ANDA Submissions — Content and Format of Abbreviated New Drug Applications: Guidance for Industry – Final |
12 June 2019 |
Applications for Premarket Review of New Tobacco Products – Draft |
11 June 2019 |
Premarket Tobacco Product Applications for Electronic Nicotine Delivery Systems (ENDS): Guidance for Industry – Final |
11 June 2019 |
Enhancing the Diversity of Clinical Trial Populations — Eligibility Criteria, Enrollment Practices, and Trial Designs Guidance for Industry – Draft |
06 June 2019 |
Enhancing the Diversity of Clinical Trial Populations — Eligibility Criteria, Enrollment Practices, and Trial Designs Guidance for Industry – Draft |
06 June 2019 |
Nonalcoholic Steatohepatitis with Compensated Cirrhosis: Developing Drugs for Treatment Guidance for Industry – Draft |
06 June 2019 |
Draft Guidance for Industry: Evaluating Alternate Curricula for the Standards for the Growing, Harvesting, Packing, and Holding of Produce for Human Consumption – Draft |
03 June 2019 |
CPG Sec. 651.100 Ethylenediamine Dihydroiodide (EDDI) – Final |
01 June 2019 |
Upcoming Meetings (* = New) |
* |
Vaccines and Related Biological Products Advisory Committee November 8, 2019 Meeting Announcement – 11/08/2019 – 11/08/2019 |
* |
November 6-7, 2019: General Hospital and Personal Use Devices Panel of the Medical Devices Advisory Committee Meeting Announcement – 11/06/2019 – 11/07/2019 |
* |
October 30, 2019: Meeting of the Bone, Reproductive and Urologic Drugs Advisory Committee Meeting Announcement – 10/30/2019 – 10/30/2019 |
* |
October 16, 2019: Antimicrobial Drugs Advisory Committee Meeting Announcement – 10/16/2019 – 10/16/2019 |
* |
Vaccines and Related Biological Products Advisory Committee October 9, 2019 Meeting Announcement – 10/09/2019 – 10/09/2019 |
* |
September 27, 2019: Meeting of the Pediatric and Drug Safety and Risk Management Committees – 09/27/2019 – 09/27/2019 |
* |
September 26, 2019: Meeting of the Pediatric and Drug Safety and Risk Management Advisory Committees – 09/26/2019 – 09/26/2019 |
* |
September 18, 2019: Meeting of the Nonprescription Drugs Advisory Committee Meeting Announcement – 09/18/2019 – 09/18/2019 |
* |
Allergenic Products Advisory Committee September 13, 2019 Meeting Announcement – 09/13/2019 – 09/13/2019 |
* |
September 10, 2019: Patient Engagement Advisory Committee Meeting Announcement – 09/10/2019 – 09/10/2019 |
|
|
|